云南白药(000538) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 10,841,237,721.29, representing a year-on-year increase of 0.62% compared to CNY 10,774,290,921.49 in the same period last year[9]. - Net profit attributable to shareholders for Q1 2025 was CNY 1,934,639,584.60, an increase of 13.67% from CNY 1,701,931,446.00 in the previous year[9]. - The net profit after deducting non-recurring gains and losses was CNY 1,887,406,845.46, up 11.65% from CNY 1,690,411,601.12 year-on-year[9]. - The industrial revenue for Q1 2025 was CNY 4.47 billion, with a year-on-year growth of CNY 317 million, resulting in a growth rate of 7.63%[9]. - The gross profit margin for the industrial segment was 68.34%, an increase of 1.76 percentage points compared to the same period last year[9]. - Total operating revenue for the current period reached ¥10,841,237,721.29, an increase from ¥10,774,290,921.49 in the previous period, reflecting a growth of approximately 0.62%[28]. - Operating profit for the current period is CNY 2,255,305,450.43, up from CNY 1,918,019,878.04, reflecting a growth of approximately 17.6%[29]. - The total comprehensive income attributable to the parent company is CNY 1,934,668,054.49, compared to CNY 1,700,922,114.44 in the previous period, indicating an increase of about 13.7%[30]. Cash Flow and Assets - The net cash flow from operating activities increased by 35.39% to CNY 713,597,559.65, compared to CNY 527,059,804.98 in the same period last year[9]. - The company's cash and cash equivalents increased to ¥11,061,687,096.94 from ¥10,887,983,161.30, showing a growth of approximately 1.59%[25]. - The company's retained earnings increased to ¥18,915,978,970.36 from ¥16,981,339,385.76, reflecting a growth of about 11.41%[28]. - The company's total assets at the end of Q1 2025 were CNY 54,253,026,317.64, reflecting a 2.53% increase from CNY 52,914,181,333.05 at the end of the previous year[9]. - Total liabilities decreased to ¥13,458,057,151.71 from ¥14,048,096,770.78, a reduction of approximately 4.20%[27]. - The company's cash flow from operating activities shows a net inflow of CNY 713,597,559.65, compared to CNY 527,059,804.98 in the previous period, marking an increase of about 35.3%[31]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 170,416[16]. - Yunnan State-owned Equity Operation Management Co., Ltd. holds 26.20% of shares, totaling 467,431,774 shares, with 115,500,000 shares pledged[16]. - Xinhua Duhua Industrial Group Co., Ltd. holds 24.42% of shares, totaling 435,742,244 shares, with 336,894,000 shares pledged[16]. - The top 10 shareholders hold significant stakes, with the largest shareholder holding over 26%[16]. - The company is actively managing shareholder equity, including pledges and releases, to optimize capital structure[21][22]. Operational Metrics - The weighted average return on equity increased by 0.68 percentage points to 4.86% from 4.18% year-on-year[9]. - The company reported a significant increase in accounts receivable by 10.08% to CNY 10,923,656,861.70, primarily due to an increase in the commercial segment's receivables[13]. - Inventory decreased to ¥5,970,435,025.83 from ¥6,294,368,316.30, reflecting a decline of approximately 5.15%[25]. - Research and development expenses for the current period were ¥60,122,221.90, compared to ¥57,282,132.50 in the previous period, showing an increase of about 3.22%[28]. Corporate Actions - The company announced the retirement of its Chief Innovation Officer and Chief Compliance Officer due to reaching the legal retirement age[20]. - The company completed the establishment of the Yunnan Traditional Chinese Medicine Health Innovation Equity Investment Fund, with registration and private fund filing completed[19]. - Yunnan State-owned Equity Operation Management Co., Ltd. released 52,171,840 shares (2.92% of total shares) from pledge on January 10, 2025[21]. - Yunnan State-owned Equity Operation Management Co., Ltd. pledged 48,000,000 shares (2.69% of total shares) on January 18, 2025[22]. - Yunnan State-owned Equity Operation Management Co., Ltd. completed a share buyback of 17,807,463 shares, representing 0.9980% of total shares, with a total investment of RMB 950,379,399.02[23].